Mineralys Therapeutics (MLYS) Operating Expenses (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Operating Expenses of $45.3 million for Q1 2026, up 18.44% sequentially from $38.3 million in Q4 2025, and up 2.01% YoY from $44.4 million in Q1 2025.
Mineralys Therapeutics (MLYS) Operating Expenses (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Operating Expenses for 5 years, with the latest figure at $45.3 million in Q1 2026.
- Quarterly Operating Expenses rose 2.01% year-over-year to $45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $171.5 million (down 14.88% YoY) and the FY2025 annual result came in at $170.6 million, down 11.33% from the prior year.
- Operating Expenses advanced to $45.3 million in Q1 2026 per MLYS's latest filing, from $38.3 million in the prior quarter.
- Over five years, Operating Expenses peaked at $60.1 million in Q3 2024 and troughed at $6.5 million in Q2 2022.
- A 5-year average of $30.9 million and a median of $35.4 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 253.94% in 2023, then tumbled 31.57% in 2025.
- Over 5 years, Operating Expenses stood at $10.0 million in 2022, then surged by 176.89% to $27.7 million in 2023, then jumped by 86.81% to $51.8 million in 2024, then dropped by 26.05% to $38.3 million in 2025, then rose by 18.44% to $45.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $45.3 million, $38.3 million, and $41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 246.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 246.04 Mn |
| Mar 31, 2026 | 45.34 Mn |
| Dec 31, 2025 | 38.28 Mn |
| Sep 30, 2025 | 41.13 Mn |
| Jun 30, 2025 | 46.75 Mn |
| Mar 31, 2025 | 44.45 Mn |
| Dec 31, 2024 | 51.77 Mn |
| Sep 30, 2024 | 60.11 Mn |
| Jun 30, 2024 | 45.17 Mn |
| Mar 31, 2024 | 35.36 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Sep 30, 2023 | 26.27 Mn |
| Jun 30, 2023 | 15.74 Mn |
| Mar 31, 2023 | 14.94 Mn |
| Dec 31, 2022 | 10.01 Mn |
| Sep 30, 2022 | 7.42 Mn |
| Jun 30, 2022 | 6.48 Mn |
| Mar 31, 2022 | 7.57 Mn |